PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:30 UTC
-
New drug combo shows promise in ovarian cancer trial
Disease control OngoingThis early-stage trial tests whether adding the drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for people with advanced ovarian cancer. About 25 patients with stage III or IV disease will receive the combination before surgery. The go…
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo shows promise for returning ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, peritoneal, or fallopian tube cancer that had returned after initial treatment. The goal was to see if the drugs could slow or stop tumor growth by blocking enzymes cancer cells need …
Matched conditions: PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC